Duac Once Daily 10 mg/g + 30 mg/g Gel is indicated for the topical treatment of mild to moderate acne vulgaris, particularly inflammatory lesions, in adults and adolescents aged 12 years and above (see sections 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Duac Once Daily Gel is indicated for the topical treatment of mild to moderate acne vulgaris, particularly inflammatory lesions, in adults and adolescents aged 12 years and above (see sections 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Treatment with saruparib (AZD5305) demonstrated encouraging efficacy, favorable safety, a wide therapeutic index, and improved pharmacokinetic properties compared with currently approved PARP inhibitors in patients with advanced solid tumors harboring BRCA1/2, PALB2, or RAD51C/D mutations, according to findings from the phase 1/IIa PETRA study (NCT04644068) presented at the American Association for Cancer Research (AACR) 2024 Annual Meeting.
Gilead Sciences, Inc. announced results from the DISCOVER trial, a two-year Phase III randomized, controlled, double-blind study evaluating the safety...
Merck Inc has announced top-line results from the company’s Phase III pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily...
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg plus Abacavir/Lamivudine once daily...
This trial is conducted in Africa, Asia, Europe and South and North America. The aim of the trial is to evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD (thiazolidinedione)...
Pfizer Inc. has announced that the FDA has approved Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily...
GlaxoSmithKline plc and Innoviva, Inc. announced that the FDA has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under...
GlaxoSmithKline has announced the submission of a New Drug Application in the US for the once daily inhaled corticosteroid treatment,...